Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer, but the treatment is not curative and most men progress to mCRPC.

Treatment with CAB plus prednisone improves OS in patients with mCRPC whose disease has progressed during or after docetaxel-based therapy.

Please sign in to read more